Know Cancer

forgot password

Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

Phase 2
18 Years
Not Enrolling
Head and Neck Cancer

Thank you

Trial Information

Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

Inclusion Criteria:

- All previously irradiated patients with recurrent head and neck cancer with no
clinically measurable distant disease or those patients in whom distant disease was
of low volume and local and regional palliation is clinically warranted. Low volume
metastatic disease is defined as asymptomatic or minimally symptomatic disease that,
according to physician judgment and without therapy for locoregionally recurrent
disease, is unlikely to effect the subject's quality or quantity of life.

- Histologic or cytological documentation of recurrent head and neck cancer requiring
regional therapy.

- Prior radiation therapy completed > 4 months before to study entry, if patients have
recovered from all side effects grade 1.

- Predominance of disease that is amenable to radiotherapy.

- Measurable disease prior to induction chemotherapy.

- Age >18 years

- Life expectancy of greater than 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky > 70%).

- Patients must have normal organ and marrow function as defined below:

Leukocytes >3,000/ul Absolute neutrophil count >1,500/ul Platelets >100,000/ul Total
bilirubin < 1.5X institutional upper limit of normal AST (SGOT)/ALT(SGPT) < 2.5 X
institutional upper limit of normal Creatinine Clearance (CrCl) > 45 mL/min

The standard Cockcroft and Gault formula (based on actual weight) or the measured
glomerular filtration rate (GFR) using the appropriate radiolabeled method (51-CrEDTA or
Tc99m-DTPA) must be used to calculate CrCl for enrollment or dosing. The same method used
at baseline should be used throughout the study. Insufficient numbers of patients have
been studied with creatinine clearance <45 mL/min to give a dose recommendation.
Therefore, pemetrexed should not be administered to patients whose creatinine clearance is
<45 mL/min.

Although ibuprofen and other non-steroidal inflammatory drugs (NSAID) can be administered
with pemetrexed in patients with normal renal function (creatinine clearance 80 mL/min),
caution should be used when administering NSAID concurrently with pemetrexed to patients
with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
Patients with mild to moderate renal insufficiency should avoid taking NSAID with short
elimination half lives (e.g. ibuprofen) for a period of 2 days before, the day of, and 2
days following administration of pemetrexed. In the absence of data regarding potential
interaction between pemetrexed and NSAID with longer half lives, all patients taking these
NSAID should interrupt dosing for at least 5 days before, the day of, and 2 days following
pemetrexed administration. If concomitant administration of an NSAID is necessary,
patients should be monitored closely for toxicity, especially myelosuppression, renal, and
gastrointestinal toxicity.

- The presence of a significant infection or another severe complicating medical
illness may constitute a contraindication to entrance on this protocol.

- Pregnancy is an absolute contraindication for this treatment protocol.

- Ability to understand and the willingness to sign a written informed consent document

- Ability to swallow vitamins and dexamethasone or willingness to use a feeding tube to
ingest these agents

Exclusion Criteria:

Previously untreated patients are not eligible

Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin
C) prior to entering the study or those who have not recovered from adverse events due to
agents administered more than 4 weeks earlier.

Patients may not be receiving any other investigational agents.

History of allergic reactions attributed to compounds of similar chemical composition
agents used in the study.

Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Primary objective is to determine 1-year survival of previously irradiated Head/Neck Cancer patients with loco-regional recurrent disease treated with induction chemotherapy with pemetrexed and gemcitabine followed by concomitant pemetrexed, carboplat

Outcome Time Frame:

1-3 years

Safety Issue:


Principal Investigator

Ezra Cohen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The University of Chicago Medical Center


United States: Food and Drug Administration

Study ID:




Start Date:

June 2005

Completion Date:

July 2010

Related Keywords:

  • Head and Neck Cancer
  • Recurrent head and neck cancer
  • larynx, lip, oral cavity and pharynx
  • Head and Neck Neoplasms



The University of Chicago Medical Center Chicago, Illinois  60637-1470